Financial Performance - The company's operating revenue for the reporting period was ¥656,743,810.69, a decrease of 17.96% compared to ¥800,552,160.04 in the same period last year[22]. - The net profit attributable to shareholders was ¥117,207,847.77, down 60.54% from ¥297,037,103.38 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was ¥105,610,344.41, a decline of 59.35% compared to ¥259,829,636.24 in the previous year[22]. - The net cash flow from operating activities was ¥136,429,704.54, representing a decrease of 57.78% from ¥323,154,330.91 in the same period last year[22]. - The gross profit margin for the pharmaceutical segment was 74.79%, down 5.62% from the previous year, with revenue declining by 29.95%[54]. - The company's revenue for the reporting period was ¥656,743,810.69, a decrease of 17.96% compared to ¥800,552,160.04 in the same period last year[52]. - The net profit for the first half of 2023 was CNY 117,207,847.77, a decrease of 60% compared to CNY 297,037,103.38 in the same period of 2022[166]. - The total revenue for the first half of 2023 was CNY 656,743,810.69, a decrease of 18% compared to CNY 800,552,160.04 in the same period of 2022[165]. Assets and Liabilities - Total assets at the end of the reporting period increased by 35.63% to ¥5,603,973,301.08 from ¥4,131,859,509.89 at the end of the previous year[22]. - The net assets attributable to shareholders rose by 14.27% to ¥2,939,222,838.92 from ¥2,572,174,931.79 at the end of the previous year[22]. - Total liabilities increased to ¥2,664,750,462.16, up from ¥1,559,684,578.10 at the end of last year[160]. - The company's total liability of CNY 2,059,175,953.45 as of June 30, 2023, compared to CNY 863,162,800.96 at the beginning of the year, indicating a significant increase[164]. Research and Development - Research and development investment increased by 41.08% to ¥47,634,586.43, driven by the strategy to enhance R&D capabilities[52]. - The company has established a stable and sustainable product development pipeline, transitioning from generic drugs to high-end generics with high technical barriers[49]. - The company has entered the registration process for 5 products and has 11 products under research, focusing on cardiovascular, digestive, and neurological systems[41]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new biopharmaceutical products in 2023[68]. - Research and development expenses increased by 30%, totaling 150 million RMB, focusing on innovative drug formulations[136]. Market and Product Development - The company is focusing on the "one vertical and one horizontal" development strategy, increasing R&D investment and enhancing market integration[30]. - The company has identified five key pharmaceutical products for development, responding to market needs and regulatory changes[34]. - The company has three core production processes for Vitamin D3, which have received national awards and are at the international leading level[43]. - The company has completed a strategic acquisition of a smaller biotech firm for 300 million yuan, enhancing its product portfolio and market reach[68]. - New product launches are expected to contribute an additional 100 million yuan in revenue by the end of 2023, with three new products scheduled for release[68]. Strategic Initiatives - The company has built stable long-term strategic partnerships with internationally renowned manufacturers and distributors, enhancing its market channels[47]. - The company has actively responded to provincial procurement tenders, adding 8 new selected provinces for Valsartan Amlodipine Tablets during the reporting period[36]. - The company is considering strategic acquisitions to enhance its product portfolio and market reach[135]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[181]. Risks and Challenges - The company faces risks related to project investments, as uncertainties in construction progress, implementation, and outcomes could impact strategic development and operational scale[79]. - There is a heightened demand for high-quality talent in research, production, sales, and management due to the company's strategic development, which poses risks in management and human resource integration[79]. - The company faces risks from changes in medical reform policies, which could lead to a decline in operating performance if not adapted timely[80]. - There is a risk of declining drug prices due to government efforts to reduce medical costs, potentially impacting the company's profitability as average profit margins in the pharmaceutical industry may decrease[80]. Environmental and Compliance - The company has been recognized as one of the first four key industry environmental "leading" demonstration enterprises in Zhejiang Province[91]. - The company maintains compliance with environmental standards, with all monitored pollutants reported as not exceeding regulatory limits[91]. - The company has established a green development philosophy focusing on source reduction, process control, and end treatment of waste[91]. - The company invested CNY 1.74257 million in environmental governance and protection during the reporting period, and paid CNY 3,753.29 in environmental protection tax[96]. Shareholder Information - The company reported a cash dividend distribution of RMB 1.40 per 10 shares, totaling RMB 77,141,057.98 for the fiscal year 2022[149]. - The employee stock ownership plan includes 119 core management and key employees holding a total of 7,674,790 shares, representing 1.39% of the company's total equity[87]. - The company confirmed a share-based payment expense of approximately CNY 13.68 million for the employee stock ownership plan during the reporting period[88]. - The total number of shares outstanding is 551,007,557, with 98.41% being unrestricted shares[131].

浙江花园生物高科股份有限公司 2023 年第一季度报告 | 证券代码：300401 | 证券简称：花园生物 | 公告编号：2023-030 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物高科股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 浙江花园生物高科股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | ...

Financial Performance - The company's operating revenue for 2022 was ¥1,417,511,816.01, representing a 26.89% increase compared to ¥1,117,099,893.11 in 2021[20]. - The net profit attributable to shareholders decreased by 20.68% to ¥383,722,581.79 from ¥479,829,624.81 in the previous year[20]. - The net profit after deducting non-recurring gains and losses increased by 34.66% to ¥348,567,290.39, up from ¥254,918,385.95 in 2021[20]. - The net cash flow from operating activities was ¥377,039,761.35, a decrease of 26.40% from ¥504,029,922.29 in 2021[20]. - The total assets at the end of 2022 were ¥4,131,859,509.89, reflecting a 17.05% increase from ¥3,525,311,449.31 at the end of 2021[20]. - The net assets attributable to shareholders increased by 12.68% to ¥2,572,174,931.79 from ¥2,278,749,932.36 in 2021[20]. - The basic earnings per share decreased by 21.35% to ¥0.70 from ¥0.88 in the previous year[20]. - The company reported a significant decline in quarterly net profit, with the fourth quarter showing only ¥29,932,598.25 compared to ¥151,152,689.96 in the first quarter[22]. - The company reported a net cash flow from financing activities surged by 451.01% to ¥43,990,014.48, compared to a net outflow of ¥12,532,243.05 in 2021[74]. Dividend and Shareholder Information - The company reported a total of 551,007,557 shares, with a cash dividend of 1.40 CNY per 10 shares (including tax) for all shareholders[5]. - The company has not proposed any stock bonus distribution, indicating a focus on cash dividends instead[5]. - The cash dividend distribution was executed on May 18, 2022, following the approval at the annual general meeting[135]. - The total number of shares for the dividend distribution is based on 551,007,557 shares[134]. - The company confirmed a shareholding plan involving 119 core management and key employees, holding a total of 7,674,790 shares, which is 1.39% of the total share capital[136]. - The employee stock ownership plan recognized a share-based payment expense of RMB 6,840,858.78 during the reporting period[137]. Research and Development - The company is actively involved in the research and development of innovative drugs, particularly in the vitamin D3 category[12]. - The company has established three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrialization research, and cutting-edge drug trials[43]. - The number of R&D personnel increased by 16.06% to 159 in 2022, reflecting the company's commitment to enhancing its research capabilities[70]. - Research and development expenses increased by 18.66% to ¥70,343,069.11, compared to ¥59,280,575.57 in 2021[56]. - The company is actively pursuing multiple R&D projects aimed at enriching its product line and enhancing market competitiveness, with several projects already approved for market entry[69]. Market and Product Development - The company aims to expand its market presence and enhance product offerings, focusing on the development of new technologies and products in the vitamin D3 segment[12]. - The demand for food and pharmaceutical-grade vitamin D3 has significantly increased due to rising health awareness, with less price volatility compared to feed-grade products[33]. - The company plans to raise 1.2 billion yuan through convertible bonds to support the industrialization of the full-active VD3 project and expand its vitamin product portfolio[35]. - The pharmaceutical segment focuses on high-barrier formulations for chronic diseases, with a strategy aligned with national medical reform policies[34]. - The company has completed the layout of the entire vitamin D3 industry chain, becoming the only global producer with a full industry chain for vitamin D3[46]. Risk Factors - The company has outlined potential risks in its future development outlook, which investors should be aware of[5]. - The company faces significant risks related to Vitamin D3 price fluctuations, as its revenue from Vitamin D3 and similar products constitutes a high proportion of total revenue[95]. - Project investment risks are present due to uncertainties in construction progress, implementation, and effectiveness, despite the company's strong technical foundation[95]. - The ongoing medical reform in China may alter the market competition landscape, posing a risk to the company's operational performance if it fails to adapt[96]. - The government’s efforts to lower drug prices may lead to a continued downward trend in drug prices, negatively impacting the company's profitability[96]. Corporate Governance and Management - The company emphasizes the importance of quality management practices in its production processes, adhering to GMP standards[12]. - The company has established a robust governance structure with independent directors overseeing its strategic direction[120]. - The company maintains a complete and independent operational system, ensuring no interference from the controlling shareholder in its business activities[109]. - The company has a diverse board with members having extensive backgrounds in economics and management[113][114][115]. - The company experienced changes in its board and management, including the resignation of the deputy general manager on January 28, 2022, due to retirement[112]. Environmental Responsibility - The company has established a comprehensive wastewater treatment system, effectively managing various types of wastewater[147]. - The company has been recognized as one of the first four key industry environmental "leading" demonstration enterprises in Zhejiang Province[147]. - The company has implemented a green development philosophy focusing on source reduction, process control, and end treatment of waste[147]. - The company’s emissions for ammonia nitrogen in wastewater were reported at 0.611 mg/l, well below the standard limit of 35 mg/l[145]. - The company has implemented energy-saving machinery to reduce electricity consumption as part of its carbon emission reduction measures[152]. Employee and Social Responsibility - The company adheres to labor laws and pays full social insurance for employees, focusing on their health and satisfaction[155]. - The company is committed to social responsibility, contributing to local economic development and job creation[157]. - The company has established a comprehensive training system, including onboarding, general skills, management skills, and professional skills training programs[132]. - The company implemented a compensation system focused on responsibility, ability, and performance to encourage employees to contribute positively to the company's profitability and development[131]. Strategic Initiatives - The company has a strategic goal of "producing one generation, researching one generation, and reserving one generation" in its pharmaceutical manufacturing sector[44]. - The company emphasizes a strategy of vertical and horizontal development to enhance its innovation capabilities in the pharmaceutical and health sectors[93]. - The company plans to ensure stable production operations and meet customer order demands in 2023[93]. - The company aims to complete the construction of a 6,000 tons vitamin A project and a 200 tons biotin project in 2023 as part of its convertible bond fundraising projects[93].

浙江花园生物高科股份有限公司 2022 年年度报告全文 浙江花园生物高科股份有限公司 2022 年年度报告 2023 年 3 月 1 浙江花园生物高科股份有限公司 2022 年年度报告全文 2022 年年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个 别和连带的法律责任。 公司负责人邵徐君、主管会计工作负责人吴春华及会计机构负责人(会计 主管人员)姚丽锦声明：保证本年度报告中财务报告的真实、准确、完整。所 有董事均已出席了审议本报告的董事会会议。 公司在本报告第三节"管理层讨论与分析"中"十一、公司未来发展展 望"部分，描述了公司经营中可能存在的风险，敬请投资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 551,007,557 股为基 数，向全体股东每 10 股派发现金红利 1.40 元（含税），送红股 0 股（含税）， 以资本公积金向全体股东每 10 股转增 0 股。 2 | 第一节 重要提示、目录和释义 2 | | | --- | --- | | 第二节 公司简介和主 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-026 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物高科股份有限公司 关于举行 2022 年度业绩网上说明会的公告 （问题征集专题页面二维码） 特此公告。 浙江花园生物高科股份有限公司董事会 2023 年 3 月 27 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江花园生物高科股份有限公司（以下简称"公司"）定于 2023 年 4 月 10 日（星 期一）下午 15:00-17:00 在全景网举办 2022 年度网上业绩说明会。本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长邵徐君、董事兼花园药业总经理 方福生、董事会秘书喻铨衡、财务总监吴春华、独立董事邵毅平、保荐代表人郭鑫。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向 投资者公开征集问题，广泛 ...

浙江花园生物高科股份有限公司 投资者关系活动记录表 证券代码：300401 证券简称：花园生物 编号：2018-001 | --- | --- | --- | |--------------------|-------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

浙江花园生物高科股份有限公司 投资者关系活动记录表 证券代码：300401 证券简称：花园生物 编号：2020-001 | --- | --- | --- | --- | |--------------------|---------------------------------------------------------------------|--------------------------------|------------------------------------------------------------------| | 投资者关系活动类别 | □ 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 \n√ 现场参观 □其他 | | □分析师会议 \n□ 业绩说明会 \n□路演活动 | | 参与单位名称及人员 | | | 国泰基金：钱晓杰 万家基金：汪洋 华泰证券：虞志豪 | | 时 间 | 2020 年 12 月 21 日 | | | | 地 点 | 浙江东阳公司会议室 | | | | 上市公司接待人员 | | 董事副总董秘喻铨衡，证代梁继富 | | | 投资者关系活动主要 ...

Company Overview and Strategy - The company is a national high-tech enterprise with over 20 years of development, having completed the full industrial chain layout for Vitamin D3, making it the only global enterprise with a full Vitamin D3 industrial chain [1] - The company has set a "one vertical, one horizontal" development strategy, focusing on building a complete Vitamin D3 upstream and downstream industrial chain (vertical) and leveraging its global market advantage for mergers and acquisitions (horizontal) [1] - The company aims to transform into a high-tech enterprise in the biopharmaceutical field while strengthening its Vitamin D3 industry, with the goal of becoming an influential player in the health sector [2] Core Products and Market Position - The company has three core products: lanolin cholesterol, 25-hydroxy Vitamin D3, and Vitamin D3 [2] - Lanolin cholesterol: The company is the only domestic enterprise with large-scale production capacity, with a design capacity of 200 tons/year, which will be expanded to 1,200 tons/year in the Jinxi Science Park [2] - 25-hydroxy Vitamin D3: Only two companies globally, including the company and Dutch DSM, can produce this product at scale. The company uses a chemical synthesis process, which has a competitive advantage over DSM's biological fermentation process. The design capacity is 100 tons/year (powder), which will be expanded to 1,200 tons/year in the Jinxi Science Park [2] - Vitamin D3: The company's traditional product, with feed-grade Vitamin D3 experiencing price fluctuations due to market consolidation, while food-grade Vitamin D3 has seen significant demand growth post-COVID-19 due to its immune-boosting properties [2] Jinxi Science Park Expansion - The Jinxi Science Park expansion includes increased production capacity for lanolin cholesterol and 25-hydroxy Vitamin D3 [2] - The South Zone of the Jinxi Science Park started production on November 11, 2020, and the East Zone is expected to be operational by the end of 2021 [3] - The company plans to prepare for the construction of a fully active Vitamin D3 (1α,25-hydroxy Vitamin D3) project after the completion of the current projects in the Jinxi Science Park [3] Market and Strategic Partnerships - The company has established long-term strategic partnerships with internationally renowned clients, including a 10-year strategic cooperation agreement with Dutch DSM for some core products [3] - The company is actively promoting the inclusion of lanolin cholesterol in the Chinese feed additive directory, which would significantly expand the market for feed-grade cholesterol [3] Relocation and Compensation - The relocation of the Xiasha production base is in the final stages of land remediation. The company has received the first and second installments of the relocation compensation, with the third installment to be paid upon land delivery to the local government [3]

浙江花园生物高科股份有限公司 投资者关系活动记录表 证券代码：300401 证券简称：花园生物 编号：2021-002 | --- | --- | --- | --- | --- | |-----------------------------|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------- ...